Scientists Seek New Tests For A Cancer On The Rise
Press Release – University of Auckland
An epidemic of womb cancer in New Zealand is being tackled by University of Auckland researchers.
Associate Professor Cherie Blenkiron and Dr Sandra Fitzgerald,who are affiliated with the University's Centre for Cancer Research, are working to develop less invasive tests for womb cancer.
'Specialists at New Zealand hospitals are seeing many more women with womb cancer and there has been a huge increase in the number of younger women diagnosed.
'Womb cancer particularly affects Māori and Pacific Island women – Pacific women have one of the highest rates in the world,' says Blenkiron, who is head of the University's Department of Molecular Medicine and Pathology.
Women who are obese or have diabetes are more likely to develop cancer of the womb.
'With the epidemic of obesity and diabetes, we're also seeing an epidemic of womb cancer,' says Blenkiron.
A decade ago, about 600 new cases of womb cancer were detected in New Zealand each year, but that has risen rapidly to about 750 a year.
It used to be regarded as a disease affecting women after menopause, but these days women as young as 30 are being diagnosed.
The national cervical screening programme was picking up 25 to 30 percent of womb cancer cases, but it has been replaced by HPV tests that don't detect womb cancer.
That means there's an urgent need to develop new womb cancer screening tests, which are not currently widely available in New Zealand, says Blenkiron.
'Our dream is to provide an accurate, affordable test that can be done in a GP clinic, possibly by the woman herself,' she says.
If womb cancer is picked up early, most women survive.
However, some women make the fatal mistake of brushing away concerns about menstrual bleeding that is excessive or that occurs between periods or after menopause. Some don't realise these are the primary symptoms of womb cancer, while others feel too shy to seek help.
In some cases, GPs struggle to know whether patients need a biopsy to determine whether they have womb cancer, says Fitzgerald.
'A less invasive test will help pick up cancers early, which will improve women's chances of survival,' she says.
Without widespread screening tests in New Zealand, women generally have to go to hospital for a biopsy to test for the cancer.
Recently, overseas researchers have devised ways to test vaginal swab samples for DNA modifications that signal cancer to try to reduce the number of women sent for unnecessary biopsies.
'We said 'look, in a number eight wire, New Zealand way, let's make that happen here',' says Blenkiron
The researchers are also working on ways to test biopsy samples to identify which type of womb cancer a patient has. These molecular tests would identify aggressive cancers that require chemotherapy and radiotherapy, as well as hysterectomy.
'We've got high hopes that test might be available for patients throughout New Zealand by next year,' says Blenkiron.
The researchers are also forging into new territory, looking at innovative ways to create world-leading tests.
The Cancer Society has just granted $250,000 for their research to identify DNA mutations that cause cancer. Blenkiron and Fitzgerald hope a swab test might be developed that is sensitive enough to detect traces of DNA mutations that have been shed from the uterus into the vagina.
Since 2021, the researchers have been looking at whether the microbiome in the vagina and uterus is different in women with cancer. They have created a test using vaginal and uterine swabs that is now being trialled on about 300 women at five hospitals in Auckland, Wellington and Christchurch.
This work is being carried out with a $175,000 grant from Auckland Medical Research Foundation and $80,000 from the Cancer Research Trust NZ.
In 2020, the Li Family Cancer Research Fund and the Centre for Cancer Research – Te Aka Mātauranga Matepukupuku granted $50,000 for the researchers to look at markers in blood samples that might point to womb cancer. This test is now being tried out on numerous samples from patients.
These potentially groundbreaking projects are likely to take longer, but the researchers hope tests might reach patients within the next 10 years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
4 hours ago
- Scoop
Sick Leave is a Right, Not a Reward: Ngarewa-Packer
Te Pāti Māori is calling out the Government's proposed changes to sick leave entitlements as a cruel step backwards that punishes low-income, part-time, single parents and essential workers. We staunchly support the concerns raised by PSA National Secretary, Fleur Fitzsimons, that this move will disproportionately harm wāhine, who are most likely to take time off to care for sick children and whānau. 'This Government's obsession with attacking women, predominantly Māori and Pacific women, ignores equity and endangers public health' said Te Pāti Māori Co-leader, Debbie Ngarewa-Packer. 'Sick leave is a right, not a reward. Cutting sick leave reinforces inequality, fuels presenteeism, and increases the risk of outbreaks in workplaces and schools. It's a betrayal of the frontline workers this country relied on during COVID-19. 'The increase to 10 days was a hard-won gain. Workers need time to recover, not punishment for being sick. Reversing this isn't 'long-needed reform' it's short-sighted austerity' said Ngarewa-Packer. Te Pāti Māori urges all parties to oppose any erosion of sick leave entitlements and stand with the workers who carry this country every day.
Scoop
6 hours ago
- Scoop
Māori Marginalised By Changes To Pae Ora Act
The Government's Cabinet-approved amendments to the Pae Ora (Healthy Futures) Act represent yet another attack on Māori aspirations for equitable health outcomes and self-determination the PSA says. The sweeping changes announced by Minister of Health Simeon Brown on 14 Pipiri (June) 2025 are regressive and undermine the intent and spirit of Te Tiriti o Waitangi and the hard-fought recognition of Māori leadership in health delivery, Te Pūkenga Here Tikanga Mahi - the Public Service Association Kaihautū Māori, Janice Panoho, says. "The Pae Ora Act was a step towards correcting decades of inequity and systemic failure in health. These amendments strip away the very mechanisms Māori advocated for and were promised, particularly the ability to shape local service design and delivery through Iwi-Māori Partnership Boards IMPBs)," says Panoho. "This is a heartless government, pushing through draconian policy under the guise of efficiency. What they call 'streamlining' is in fact the deliberate sidelining of Māori voices from decisions about Māori health. "Rather than enhancing Te Tiriti partnerships, the changes weaken Māori influence by making iwi-Māori Partnership Boards (IMPBS) mere advisors to the Hauora Māori Advisory Committee, removing their direct role in shaping services that affect their own communities. "This top-down, centralised approach reverts us to the very system that failed Māori for generations. "By repealing the Health Charter and diluting the role of IMPBs, this government is erasing the commitments to equity, kaupapa Māori, and the lived realities of whānau. It is deeply concerning," Panoho said. "We are not just stakeholders. We are tangata whenua. Health equity cannot be achieved if Māori are shut out of the rooms where decisions are made. These changes are a betrayal. Panoho says the PSA stands with Māori communities, health workers and iwi organisations in calling for the government to halt these amendments, engage in genuine consultation with Māori, and honour the promises made through Pae Ora and Te Tiriti o Waitangi. "The Government's emphasis on targets, infrastructure, and performance data ignores what Māori have said for decades, that meaningful, lasting health outcomes come from whānau-centred services designed with us, not for us. "The health system can't deliver for Māori while continuing to marginalise us. The PSA urges all political leaders, health professionals, and communities to scrutinise these changes and hold the Government accountable for actions that risk entrenching inequities even further. "He tangata akona ki te whare, tūnga ki te marae, tau ana. One who is trained at home will stand with confidence in the world. Let Māori solutions stand strong within our health system, not be cast aside once again."
Scoop
7 hours ago
- Scoop
Include Males Too In Addressing Human Papilloma Virus And Related Cancers
Press Release – CNS Human Papilloma Virus (HPV) is a common sexually transmitted infection. Since an effective HPV vaccine exists and HPV screening and treatment of pre-cancer lesions can save lives, no one should be suffering from any of the HPV related cancer or … Human Papilloma Virus (HPV) is a common sexually transmitted infection. Since an effective HPV vaccine exists and HPV screening and treatment of pre-cancer lesions can save lives, no one should be suffering from any of the HPV related cancer or had to die of it. According to the World Health Organization (WHO), HPV do not cause health concerns in most infected people (of all genders), but persistent HPV infection with some high-risk genotypes is common and can cause genital warts or cancer. For example, almost all cervical cancer, which is the 4th top cancers among women worldwide, is caused by HPV. HPV also causes cancers of vulva, vagina, mouth/throat (oropharyngeal), penis and anus. Despite cervical cancer being preventable and curable (if detected early and managed effectively), more than 660,000 women developed cervical cancer in 2022. Over 350,000 women died of cervical cancer in 2022. In 2019, HPV caused over 70,000 cancer cases in men too. HPV screening must be done with DNA test, not pap smear or VIA 'We have a large burden of cervical cancer in India – one woman dies every 8 minutes due to this preventable cancer. All women above the age of 30 years, must undergo cervical cancer screening with an HPV DNA molecular test (and not by pap smear or visual inspection with acetic acid – VIA),' said Dr Smita Joshi, a noted scientist who has made a significant contribution to advancing HPV vaccine and screening research and science-backed interventions in the past two decades. National Family Health Survey (NFHS) of India 2019-2021 shows that among women age 15-49, only 1.2% ever got a screening for cervical cancer in India. WHO Cervical Cancer Elimination Initiative (adopted in 2021) sets the goal of at least 70% of the eligible women to get screened. 'There is a large gap in HPV screening of eligible women in India,' points out Dr Joshi. Dr Joshi leads the Department of Preventive Oncology, Prayas (a non-profit). Dr Joshi has been a principal investigator for HPV vaccine and cervical cancer related research studies of WHO's IARC (International Agency for Research on Cancer) since 2009. She also serves as Programme Director at Jahangir Clinical Development Centre (JCDC) in Pune, India. Connect the dots: HPV, HIV and all genders Women living with HIV are at 6 times higher risk of HPV-related cervical cancer compared to those without HIV. HPV also infects men. For example, studies show that rates of HPV have shown to be alarmingly high among men who have sex with men. Mumbai-based microbiologist and researcher Dr Prapti Gilada-Toshinwal presented an important study at 10th Asia Pacific AIDS and Co-Infections Conference (APACC 2025) in Japan. This study was done to determine the prevalence of HPV anal infection among 105 men who have sex with men who were seeking care at Unison Medicare and Research Centre (a comprehensive infectious diseases centre) between August 2022 and December 2024. It is important to note that Unison Medicare and Research Centre has been serving around 10,000 people living with HIV since last 35 years. Around 80% study participants came from Mumbai and rest of them were from other cities of India except 3 who came from other countries. '70% of study participants were living with HIV,' said Dr Prapti Gilada. 'Overall, anal HPV infection rate was 62%.' She serves as CEO and consultant microbiologist at UniLabs Diagnostics. 'Some of them also had other sexually transmitted infections such as syphilis, chlamydia, or gonorrhoea.' 'In the study we offered DNA test for HPV to all eligible study participants (105 men who have sex with men) who were receiving medical care at our centre. Most common HPV high risk genotype was 16. Other common high-risk HPV genotypes found among study participants were 18 and 45,' said Dr Prapti Gilada. 'HPV positivity rates were higher in those study participants who were also living with HIV (68.5%) compared to those without HIV (48%),' said Dr Prapti Gilada, who is also an independent Director of Thyrocare. Global data shows that among men who have sex with men, HPV is higher among those who are living with HIV than those without it. She was speaking with CNS before 2nd Asia Pacific Conference on Point-of-Care Diagnostics for Infectious Diseases (POC 2025) and 13th International AIDS Society Conference on HIV Science (IAS 2025) open. Dr Prapti Gilada calls for raising awareness, health and treatment literacy among the masses so that eligible boys and men and girls and women can access HPV vaccination, HPV screening and management of pre-cancerous lesions and other health issues. She also hopes governments will make HPV vaccination available to all those eligible of all genders, as well as screening and appropriate management. Dr Prapti Gilada cites a study published in The Lancet in 2023 which showed that almost 1 in 3 men over the age of 15 were infected with at least one genital HPV genotype, and 1 in 5 men were infected with one or more of high risk (or oncogenic) HPV genotypes. It is high time all eligible boys and men too are included in HPV responses globally Agrees Vijay Nair who is the Chairperson of Udaan Trust and a prominent community rights activist from India: 'With no HPV vaccination and screening facilities for males, there are people who have even probably died with undiagnosed HPV-related anal cancers or other health issues. Some may be getting services for piles or anal fissures or fistula as there is hardly any HPV screening facilities for anal HPV. We need to screen high-risk men for HPV and HPV related health conditions including pre-cancerous lesions or anal cancers. Also, we need to include males too for vaccination against HPV.' Vijay was speaking at the India's National Dialogue and Stakeholder Consultation held last month in preventing cancers and addressing ageing among people living with HIV. It was organised by National Coalition of People Living with HIV in India (NCPI Plus). Colposcopy and anoscopy: Do we have enough facilities? Those with persistent HPV infection may need a specialised follow up medical examination with colposcopy (medical experts examine with an equipment for any HPV-related changes or abnormalities in vulva, vagina or cervix of women) or anoscopy (medical experts examine with an equipment for any HPV-related changes or abnormalities in anus or rectum). If any changes or abnormalities, further appropriate medical treatment is required. 'We need more medical centres for anoscopy,' said Dr Prapti Gilada whose study participants may require further follow up. Her centre is continuing to follow up with all the study participants, one of whom has become HPV negative during the study. Dr Smita Joshi is a widely recognised colposcopy trainer too. 'We have screened over 40,000 women for HPV and cervical cancer and managed them appropriately as per the WHO latest guidelines.' Her centre at Prayas is a recognised colposcopy centre too which has trained several medical professionals including gynaecologists from within India and other countries too. She appeals for financial resources to scale up trainings of medical professionals in India and other countries which would go a long way in strengthening capacities and competencies towards addressing HPV and related cancers. Addressing HPV lacks ambition Governments have promised to eliminate cervical cancer by end of this century. In order to be on track towards cervical cancer elimination, all countries must reach and maintain an incidence rate of below 4 per 100,000 women. Achieving that goal rests on 3 key pillars and their corresponding targets to be achieved by 2030 so that countries are on track towards eliminating cervical cancer by end of the century. – vaccination: 90% of all eligible young people must be fully vaccinated with the HPV vaccine by the age of 15 – screening: 70% of women should be screened using a high-performance test by the age of 35, and again by the age of 45 – treatment: 90% of women with pre-cancer treated and 90% of women with invasive cancer managed. Cervical cancer is preventable as vaccines exist since almost two decades now. HPV screening and DNA tests exist. Medical management of pre-cancerous lesions can save lives and avert cancers. Is not a goal to eliminate cervical cancer by turn of this century, lacking ambition? India's first indigenously validated Truenat HPV-HR Plus test in April 2025 Indian government announced in April 2025, India's first indigenously developed and point-of-care HPV DNA molecular test is Truenat HPV-HR Plus test that screens people for 8 high-risk genotypes (16, 18, 31, 33, 35, 45, 52 and 58). These 8 high-risk HPV genotypes cause over 96% of cervical cancers globally. Truenat HPV-HR Plus is developed by Indian company (Molbio Diagnostics). Its independent multi-centric validation was done by Government of India's Department of Biotechnology, Biotechnology Industry Research Assistance Council (BIRAC) and Grand Challenges India. This independent validation of Truenat HPV-HR Plus was conducted under the study 'Validating Indigenous Human Papilloma Virus (HPV) Tests for Cervical Cancer Screening in India.' The study involved leading Indian government's research institutes, including All India Institute of Medical Sciences (AIIMS) Delhi, ICMR National Institute for Cancer Prevention and Research (NICPR) Noida, and ICMR National Institute for Research in Reproductive and Child Health (NIRRCH) Mumbai, in collaboration with WHO's International Agency for Research on Cancer (IARC). However, Truenat HPV-HR DNA molecular test has been around for over 2 years now to screen people for 4 high-risk genotypes. Follow the science: Vaccinate and screen all eligible people for HPV and related cancers Dr Smita Joshi led several researchers in her distinguished career over two decades. She was part of a multi-centric study of WHO's IARC on HPV vaccine which was initiated in 2009 onwards. This study was to evaluate efficacy of HPV vaccine (2 doses vs 3 doses at 0, 2 and 6 months). However, due to government's order to stop HPV vaccination in studies (owing to adverse outcomes in a PATH study), Dr Joshi's study also had to stop vaccination abruptly in April 2009. 'Because of that suspension of HPV vaccinatio, instead of two versus three doses, this study resulted in a cohort of girls that had received only a single dose, two doses (at 0 and 2 months), two doses (at 0 and 6 months) and three doses (at 0, 2 and 6 months). So, the long-term follow-up of these vaccinated girls is still being carried out since then,' said Dr Joshi. 'We have now completed 15 years of the study and of immunogenicity data.' Dr Joshi's study majorly impacted and contributed to informing vaccine dosage in many countries as well as to WHO's recommendation of single dose HP vaccination in the young girls. She was also part of the HPV vaccine study (for India's indigenously developed HPV vaccine Ceravac). She wonders when HPV vaccine would become a part of Indian government's public vaccination programme. Some Indian states (like Sikkim, Delhi, Punjab) had introduced HPV vaccination using a foreign-made vaccine) but latest information on status of these programmes is not with us. Dr Prapti Gilada and Udaan's Vijay Nair too call for including HPV vaccination for those eligible from all genders in the government's programme at the earliest – as well as HPV screening and management of all related health conditions especially pre-cancerous lesions and cancers. Dr Smita Joshi adds that when government of India includes indigenously developed HPV vaccine in its programme, then 'one good thing about Ceravac of Serum Institute of India is that it is also approved for boys. Appeal to world leaders who will meet at UNHLM on NCDs Next High Level Meeting on Non-Communicable Diseases (UNHLM on NCDs) will happen in September 2025 at the United Nations General Assembly. Although HPV is an infection, yet it causes one of the top cancers worldwide. We appeal to world leaders to commit to scale up HPV vaccination for all those eligible (regardless of genders), and screen all eligible people (regardless of gender) for HPV and related pre-cancerous and cancerous conditions. Developing vaccine or point-of-care diagnostics is not enough but deploying them at point-of-need in the Global South is critical pathway towards increasing access to lifesaving services and improving HPV-related responses on the ground. Shobha Shukla – CNS (Citizen News Service) (Shobha Shukla is the award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service) and is a feminist, health and development justice advocate. She is a former senior Physics faculty of prestigious Loreto Convent College and current Coordinator of Asia Pacific Regional Media Alliance for Health and Development (APCAT Media) and Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024). She also coordinates SHE & Rights initiative (Sexual health with equity & rights). Follow her on Twitter @shobha1shukla or read her writings here
